In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
作者信息
Hong Seong Geun, Moland Ellen Smith, Wickman Paul A, Black Jennifer A, Hossain Ashfaque, Hanson Nancy D, Thomson Kenneth S
机构信息
Creighton University School of Medicine, Department of Medical Microbiology and Immunology, Center for Research in Anti-Infectives and Biotechnology, 2500 California Plaza, Omaha, NE 68178, USA.
出版信息
Antimicrob Agents Chemother. 2007 Apr;51(4):1512-4. doi: 10.1128/AAC.00959-06. Epub 2007 Jan 12.
Abstract
DQ-113 was compared in vitro to sitafloxacin, moxifloxacin, levofloxacin, and ciprofloxacin for potential to select mutational resistance in multiresistant staphylococci, pneumococci, and enterococci. Its ability to select less-susceptible mutants varied according to species, being lowest with staphylococci, intermediate with pneumococci, and greatest with enterococci.
摘要
相似文献
1
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Antimicrob Agents Chemother. 2007 Apr;51(4):1512-4. doi: 10.1128/AAC.00959-06. Epub 2007 Jan 12.
2
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
J Antimicrob Chemother. 1999 Nov;44(5):621-7. doi: 10.1093/jac/44.5.621.
3
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. doi: 10.1128/AAC.01197-09. Epub 2010 Jan 11.
4
In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci.
J Antimicrob Chemother. 2015 Jan;70(1):57-61. doi: 10.1093/jac/dku375. Epub 2014 Sep 25.
5
Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci.
Antimicrob Agents Chemother. 1994 Mar;38(3):611-5. doi: 10.1128/AAC.38.3.611.
6
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Antimicrob Agents Chemother. 2000 Mar;44(3):802-5. doi: 10.1128/AAC.44.3.802-805.2000.
7
In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
Diagn Microbiol Infect Dis. 1998 Oct;32(2):115-8. doi: 10.1016/s0732-8893(98)00078-9.
8
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Diagn Microbiol Infect Dis. 1998 Nov;32(3):247-52. doi: 10.1016/s0732-8893(98)00101-1.
9
In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Diagn Microbiol Infect Dis. 1993 Jul;17(1):85-91. doi: 10.1016/0732-8893(93)90077-k.
10
Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci.
Diagn Microbiol Infect Dis. 2001 Feb;39(2):133-5. doi: 10.1016/s0732-8893(00)00233-9.
引用本文的文献
1
Sitafloxacin: in bacterial infections.
Drugs. 2011 Apr 16;71(6):731-44. doi: 10.2165/11207380-000000000-00000.
本文引用的文献
1
Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2006 Feb;50(2):685-93. doi: 10.1128/AAC.50.2.685-693.2006.
2
Use of an efflux-deficient streptococcus pneumoniae strain panel to identify ABC-class multidrug transporters involved in intrinsic resistance to antimicrobial agents.
Antimicrob Agents Chemother. 2005 Nov;49(11):4781-3. doi: 10.1128/AAC.49.11.4781-4783.2005.
3
Microbial selection.
Science. 1952 Jul 18;116(3003):45-51.
4
In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Antimicrob Agents Chemother. 2003 Dec;47(12):3699-703. doi: 10.1128/AAC.47.12.3699-3703.2003.
5
Effects of DQ-113, a new quinolone, against methicillin- and vancomycin-resistant Staphylococcus aureus-caused hematogenous pulmonary infections in mice.
Antimicrob Agents Chemother. 2003 Dec;47(12):3694-8. doi: 10.1128/AAC.47.12.3694-3698.2003.
6
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
Antimicrob Agents Chemother. 2002 Mar;46(3):904-8. doi: 10.1128/AAC.46.3.904-908.2002.
7
Genome of the bacterium Streptococcus pneumoniae strain R6.
J Bacteriol. 2001 Oct;183(19):5709-17. doi: 10.1128/JB.183.19.5709-5717.2001.
8
Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1999 Jan;43(1):187-9. doi: 10.1128/AAC.43.1.187.
9
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Aug;42(8):2032-5. doi: 10.1128/AAC.42.8.2032.
Zotero 插件